Atezolizumab for adjuvant treatment of circulating tumour DNA-positive high-risk muscle-invasive bladder cancer after cystectomy [ID6515]

  • Awaiting development
  • GID-TA11654
  • Expected publication date: TBC

Suggested remit: To appraise the clinical and cost effectiveness of Atezolizumab with chemotherapy within its marketing authorisation for treating bladder cancer